Fine particulate matter linked to higher eczema risk

Researchers explore the association between exposure to fine particulate matter and the risk of eczema.

A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches.

February 14, 2024

FDA, CMS defend plans to increase oversight of laboratory developed tests

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration

January 19, 2024

PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine) – Psychedelic Alpha

FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO,

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.